AlzProtect was founded in 2007 by Dr. André Delacourte, one of the pioneers of research on Alzheimer's disease, and Professor Patricia Melnyk, expert in medicinal chemistry.
Alzprotect's mission is to develop medicines for the treatment of neurodegenerative diseases from research excellence proof of concept in patients and to sell the license to a pharmaceutical partner or sell the company.
AZP2006 differs from competing molecules by addressing all the causes of the disease, including Ab toxicity, Tau phosphorylation, oxidative stress and neuroinflammation.
AlzProtect aims to maintain and reinvigorate neurons that are still alive. In fact, AZP2006 is intended to be preventative and curative, rather than palliative: AZP2006 is an intraneuronal, non-synaptic drug capable of suspending the progression of Alzheimer's disease.
In addition to AZP2006, AlzProtect has identified three other molecules :
- AZP5088 for the treatment of Alzheimer’s disease
- AZP7015 dedicated to frontotemporal dementia
- AZP13005 for the treatment of Parkinson's disease